Managing Partner, Montreal and Munich
Dr. Birner is responsible for TVM Capital Life Science’s overall investment strategy and global fund operations.
Dr. Birner joined TVM Capital in 2000 as an investment manager. He currently serves as Co-Chairman of the board of directors of CENTOGENE AG, Chairman of the board of SpePharm Holdings BV, leon nanodrugs GmbH and AL-S Pharma AG. He is also a member of the board of directors of Acer Therapeutics Inc. Dr. Birner previously served on the board of directors of Argos Therapeutic, Horizon Pharma, Inc., Bioxell SA, Evotec AG, Noxxon Pharma, Probiodrug AG, Proteon Therapeutics Inc. and Jerini AG.
Prior to his current tenure, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca Agrochemicals. Dr. Birner joined Zeneca from McKinsey & Company’s European Health Care and Pharmaceutical practice. As a management consultant he gained extensive experience in R&D management, marketing and sales, and joint venture structuring and business development.
Before starting his professional career in business, he earned substantial academic merits, including a position as Assistant Professor for biochemistry at the Ludwig-Maximilian-University (LMU), following his summa cum laude doctoral degree in biochemistry at LMU; his doctoral thesis was honoured with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases. Dr. Birner also holds an MBA from Harvard Business School.